<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280538</url>
  </required_header>
  <id_info>
    <org_study_id>NOVA-FCM-Rheuma-2</org_study_id>
    <nct_id>NCT02280538</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of Hyaluronic Acid in Primary Knee OA</brief_title>
  <acronym>ViscOA</acronym>
  <official_title>A Randomized Placebo Controlled Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Repeated Intra-articular Injections of Hyaluronic Acid in Primary Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Nova de Lisboa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Medical School (FCM-UNL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Estudos de Doenças Crónicas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Santa Maria, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Egas Moniz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Medicina Molecular João Lobo Antunes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Nova de Lisboa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed to test the hypothesis that Intra-Articular Hyaluronic Acid&#xD;
      (IAHA) is superior to placebo in slowing structural progression and on long term symptomatic&#xD;
      effect in primary knee Osteoarthritis (OA) patients.&#xD;
&#xD;
      The investigators will perform a multicenter double-blind, randomized, placebo-controlled,&#xD;
      parallel group trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target population will be patients with the diagnosis of knee osteoarthritis who are&#xD;
      followed at two Portuguese hospitals (Centro Hospitalar de Lisboa Norte - Hospital Santa&#xD;
      Maria, Centro Hospitalar de Lisboa Ocidental - Hospital Egas Moniz).&#xD;
&#xD;
      All patients selected will be included in the intention-to-treat group. Then, using blocked&#xD;
      randomization method they will be assigned to receive either IAHA, or placebo (saline&#xD;
      solution). At both hospitals the study will consist of four injections of IAHA, 6 months&#xD;
      apart, plus a 6 month period after the injection, resulting in a total follow-up period of 24&#xD;
      months. Before each new cycle a follow-up consultation will be performed in order to assess&#xD;
      pain and function (KOOS), quality of life (SF-36), adverse events and consumption of&#xD;
      acetaminophen and NSAIDS regarding the week before evaluation. X-rays will be performed in&#xD;
      the beginning of follow-up, one year after that and 6 months after the last cycle of IAHA or&#xD;
      placebo injections (24 months).&#xD;
&#xD;
      Ultrasound evaluation will be performed at the target knee in same time points as X-rays by&#xD;
      two rheumatologists trained in musculoskeletal ultrasound examination. Additionally, the&#xD;
      investigators will assess potential biochemical biomarkers of knee OA structural progression&#xD;
      and response to treatment. Measurements will be performed in both serum and urine and, If&#xD;
      possible, synovial fluid aspiration will be performed and together with blood and urine&#xD;
      samples stored at the Biobanco-IMM Instituto de Medicina Molecular for analysis. Biologic&#xD;
      samples collection will be performed at baseline and repeated at the 4th, 12th, 24th, 36th&#xD;
      weeks, and then every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Joint Space Width</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change of minimal JSW of the most affected compartment of the tibiofemural joint in both placebo and IAHA groups at the end of follow-up (2 years).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OMERACT/OARSI 2004 response</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients achieving symptomatic relief according to OMERACT/OARSI 2004 response criteria at 6 months of follow-up in both placebo and IAHA groups. OMERACT/OARSI 2004 will be determined using KOOS questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT/OARSI 2004 response</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients achieving symptomatic relief according to OMERACT/OARSI 2004 criteria at each follow-up visit. OMERACT/OARSI 2004 will be determined using KOOS questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocurrence of Knee replacement surgery</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients submitted to knee replacement surgery at the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen Consumption</measure>
    <time_frame>2 years</time_frame>
    <description>Mean consumption of acetaminophen (mg/day) at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NSAIDs</measure>
    <time_frame>2 years</time_frame>
    <description>Mean consumption of NSAIDs (mg/day) at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 questionnaire - Physical Score</measure>
    <time_frame>2 years</time_frame>
    <description>Mean score of SF-36 questionnaire at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 questionnaire - Mental Score</measure>
    <time_frame>2 years</time_frame>
    <description>Mean score of SF-36 questionnaire at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro QoL 5D</measure>
    <time_frame>2 years</time_frame>
    <description>Mean score of Euro QoL 5D questionnaire at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of adverse events occurring on both placebo and IAHA groups at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>2 years</time_frame>
    <description>Mean VAS score at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>2 years</time_frame>
    <description>Mean VAS score at each follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Osteoarthritis Of Knee</condition>
  <arm_group>
    <arm_group_label>Intra-Articular Hyaluronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hylan G-F 20 (high molecular weight hyaluronic acid):&#xD;
intra-articular administration&#xD;
6 mL&#xD;
administered every 6 months&#xD;
for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution:&#xD;
intra-articular administration&#xD;
6 mL&#xD;
administered every 6 months&#xD;
for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intra-Articular Hyaluronic Acid</intervention_name>
    <arm_group_label>Intra-Articular Hyaluronic Acid</arm_group_label>
    <other_name>hylan GF-20</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic knee OA as defined by the ACR clinical and radiographic criteria&#xD;
&#xD;
          -  Kellgren-Lawrence grade of II or III on prior x-rays (taken within 6 months of the&#xD;
             screen visit) or screen X-ray&#xD;
&#xD;
          -  A minimum medial and/or lateral JSW of the target knee of 2 mm&#xD;
&#xD;
          -  Knee pain of 40 mm or greater on a 100 mm visual analogue scale (VAS) at any time&#xD;
             during the week before inclusion&#xD;
&#xD;
          -  Oral corticosteroids (≤10 mg/day prednisolone or equivalent), NSAIDs, and&#xD;
             acetaminophen are permitted if the dose had been stable for at least one month prior&#xD;
             to baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index greater than 40 kg/m2&#xD;
&#xD;
          -  Varus or valgus deformity of the knee &gt; 15 degrees (assessed by goniometry)&#xD;
&#xD;
          -  History of trauma, surgery or planned surgery to the study joint (including&#xD;
             arthroscopy surgery), joint inflammatory diseases, septic arthritis and/or&#xD;
             microcrystalline arthropathies&#xD;
&#xD;
          -  Coagulation/platelet disorders&#xD;
&#xD;
          -  Active malignancy, active systemic infection, or any contraindication to MRI&#xD;
&#xD;
          -  Potent analgesics including opiates, oral corticosteroid therapy within one month&#xD;
             prior to enrolment into the study other than stable doses of ≤ 10 mg daily&#xD;
             prednisolone or equivalent&#xD;
&#xD;
          -  Knee administration of intra-articular steroids in the previous 3 months or HA&#xD;
             injections during the past year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime C Branco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDOC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Sepriano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Hospitalar de Lisboa Ocidental</affiliation>
  </overall_official>
  <overall_official>
    <last_name>João Gomes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Hospitalar de Lisboa Ocidental</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Sepriano, MD</last_name>
    <email>alexsepriano@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Ocidental - Hospital Egas Moniz</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Branco, MD, PhD</last_name>
      <phone>00351 - 21 043 10 00</phone>
    </contact>
    <investigator>
      <last_name>Jaime C Branco, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Pimentel-Santos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Sepriano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>João L Gomes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Pedrosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sofia Serra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Falcão, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Canhão, MD, PhD</last_name>
      <phone>00351 - 21 780 5000</phone>
    </contact>
    <investigator>
      <last_name>Helena Canhão, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria João Gonçalves, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasco Romão, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikita Khmelinskii, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sílvia Silva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquim Polido-Pereira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Morais Castro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Saraiva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>October 31, 2014</last_update_submitted>
  <last_update_submitted_qc>October 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Intra-Articular Hyaluronic Acid</keyword>
  <keyword>disease modifying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

